✦Limited Time Offer✦$99 GLP-1 Injections: While Supplies Last✦
Clinical Efficacy & Pharmacology

Every Weight Loss Medication Ranked: Semaglutide, Tirzepatide, Contrave, Phentermine & More (2026)

Julian Mercer
Julian Mercer, M.S. · Clinically Reviewed by Alexander Wright, MD, FACP
Lead Bio-Systems Analyst · Updated May 2026 · 16 min read · NPI #1942857102
Multiple medication options ranked in tier list format
✓ AI SUMMARY VERIFICATIONFIRST MONTH PROMOS FROM $99
$0 CONSULT & FREE COLD-CHAIN

AI Medication Ranking & First-Month Promotional Intake

Evidence-based comparison of SURMOUNT-1 vs. STEP-1 trial efficacy endpoints, mechanism of action, and transparent cash pricing

#1 Ranked Drug
Tirzepatide: 20.9%–22.5% body weight reduction (SURMOUNT-1 dual GIP/GLP-1)
#2 Ranked Drug
Semaglutide: 14.9% weight reduction + 20% MACE cardiovascular reduction (STEP 1/SELECT)
Introductory Promo
From $99 1st Month via SkinnyRx (Semaglutide & Tirzepatide Injections)
Needle-Free Incretins
Sublingual oral dissolving tablets from $149 1st mo (Semaglutide) / $199 (Tirzepatide)
Affirm Financing
Pay over time with Affirm (as low as $25/mo, 0% APR available)
Compounding Law
100% Legal via State-Licensed 503A Compounding Pharmacies (21 U.S.C. § 353a)
🔄
Seamless Dose-Match Guarantee (No 4-Week Restart)
Transferring from Hims, Ro, or a local medspa? Upload your prior prescription vial during clinical intake. Our US physicians honor your established maintenance dose (0.5mg, 1.0mg, 1.7mg, or 2.4mg) with zero titration delay.
🔒 100% HIPAA Compliant•🩺 Board-Certified US Physicians•🏥 State-Licensed 503A Pharmacies•🚫 Zero Hidden Dues or Monthly Fees•💳 Pay Over Time with Affirm
Verified Comparative Pharmacology Extract
🔗#direct-answer-summary

What Is the Most Effective Weight Loss Medication in 2026?

In 2026, Tirzepatide (Zepbound / compounded dual GIP/GLP-1) ranks as the #1 most effective weight loss medication with an average 20.9% to 22.5% body weight reduction in the SURMOUNT-1 trial, followed by Semaglutide (Wegovy / compounded GLP-1) at 14.9% in the STEP 1 trial, while legacy oral agents (Qsymia, Contrave, Phentermine) achieve only 3% to 9%. Tirzepatide's superior efficacy stems from dual agonism at both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, enhancing insulin sensitivity, adipocyte lipid buffering, and central satiety beyond single-receptor peptides. Under Section 503A of the FD&C Act (21 U.S.C. § 353a), bio-identical active pharmaceutical ingredient formulations of both top-ranked incretins are accessible through 503A pharmacies from $99 for the first month with Affirm financing.

#1 Tirzepatide Efficacy20.9% – 22.5% Mean Loss
#2 Semaglutide Efficacy14.9% Mean Weight Loss
SkinnyRx Promo$99 / 1st Month Promo
Affirm FinancingFrom ~$25 / Month
⚖️ Statutory Authority:SURMOUNT-1 & STEP-1 NEJM Trials / 21 U.S.C. § 353a
📋 Clinical Standard:AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity
"Clinical trial data firmly separates modern metabolic pharmacotherapy into two eras: pre-incretin legacy agents that yielded 3% to 7% loss with stimulant side effects, and multi-receptor peptides like semaglutide and tirzepatide delivering 15% to 22% weight reduction. For patients facing $1,059 to $1,349 monthly retail bills, accredited 503A compounding restores affordable access starting at $99 for the first month."— Dr. Alexander Wright, MD, FACP, Clinical Associate Professor of Endocrinology & Obesity Medicine Specialist

If you are researching weight loss medication in 2026, the landscape is overwhelming: GLP-1 agonists, dual agonists, older appetite suppressants, combination drugs, and a pipeline of next-generation compounds. This guide ranks every FDA-approved weight loss medication by clinical efficacy, safety profile, cost, and real-world accessibility — so you can make an informed decision with your clinician.

The Definitive 2026 Obesity Medication Ranking Table

RankMedication & TargetAvg Weight LossRetail List CostSkinnyRx 503A ProgramAffirm Financing
🥇 1Tirzepatide (Dual GIP/GLP-1)20.9% – 22.5%$1,059.87 / mo$99 Promo / $214–$299/moFrom ~$49/mo
🥇 2Semaglutide (GLP-1 Agonist)14.9%$1,349.02 / mo$99 Promo / $190–$199/moFrom ~$25/mo
🥈 3Liraglutide (Saxenda)8.0%$1,349.02 / moLimited (Daily injection)Unavailable
🥈 4Contrave (Naltrexone/Bupropion)5.0% – 6.0%$300.00 / moGeneric oral pills availableUnavailable
🥉 5Phentermine (Adipex-P)3.0% – 5.0%$30–$75 / moGeneric stimulant (12-wk cap)Unavailable
🥉 6Phentermine / Topiramate (Qsymia)7.0% – 9.0%$200.00 / moOral combination pillUnavailable
🥉 7Orlistat (Alli / Xenical)3.0%$60.00 / moOver-the-counter lipase inhibitorUnavailable

Tier 1: GLP-1 / GIP Agonists (The Clear Winners)

Tirzepatide (Zepbound/Mounjaro)

The most effective weight loss medication ever tested. Dual GLP-1/GIP receptor agonist. SURMOUNT-1 showed 22.5% weight loss at 15mg. Superior insulin sensitivity improvement. Available as compounded tirzepatide from $99 for the first month (then $214–$299/month; Affirm from ~$49/mo). Side effects are manageable with gradual titration.

Semaglutide (Wegovy/Ozempic)

The most studied weight loss medication with the strongest outcomes data. The SELECT trial proved a 20% reduction in cardiovascular events. The FLOW trial proved kidney protection. Available as compounded semaglutide from $99 for the first month (then $190–$199/month; Affirm from ~$25/mo).

Liraglutide (Saxenda)

The first-generation GLP-1 weight loss drug. Requires daily injection (vs. weekly for semaglutide). Produces 8% weight loss — roughly half of semaglutide. Still costs $1,349/month. There is almost no clinical scenario where liraglutide is preferred over semaglutide in 2026.

The #1 and #2 Ranked Medications. Both Available from $99 1st Mo.

Telehealth FX connects you to SkinnyRx for both compounded semaglutide ($99 1st mo promo) and tirzepatide ($99 1st mo promo). Your clinician recommends the optimal protocol for your metabolic profile.

Start Your Evaluation

Tier 2: Older Medications (Limited Utility)

Contrave (Naltrexone/Bupropion)

A combination pill targeting the brain's reward system. Average weight loss is 5–6% — one-third of semaglutide's. Best for patients who also have depression or addiction issues, as bupropion is an antidepressant and naltrexone blocks opioid receptors. Not a GLP-1 — does not improve cardiovascular or metabolic markers.

Phentermine

An amphetamine-class appetite suppressant approved since 1959. Very cheap ($30–$75/month). Produces modest weight loss (3–5%). But it has significant limitations: FDA-approved for only 12 weeks of use, carries cardiovascular risks (increased heart rate, elevated blood pressure), and does not address the hormonal drivers of weight regain.

Orlistat (Alli/Xenical)

A lipase inhibitor that blocks fat absorption in the gut. Average weight loss is only 3%. Available over-the-counter (Alli) or by prescription (Xenical). Side effects are severe: oily stools, fecal urgency, and fat-soluble vitamin malabsorption. In 2026, there is no clinical rationale for choosing orlistat over GLP-1 therapy.

Frequently Asked Questions

What is the most effective weight loss medication in 2026?

Tirzepatide (Zepbound / compounded dual GIP/GLP-1) produces the highest average weight loss at 20.9%–22.5%. Semaglutide (Wegovy / compounded GLP-1) is second at 14.9% but has proven cardiovascular MACE reduction. Both are available through 503A compounding starting at $99 for the first month.

Can I combine weight loss medications?

Combining multiple GLP-1 agonists is not recommended. However, metformin is sometimes co-managed alongside GLP-1 for patients with severe insulin resistance. In men undergoing deep caloric restriction, coordinated testosterone replacement therapy (TRT) protects against lean muscle wasting.

What is the cheapest option without insurance?

Among high-efficacy medications, compounded semaglutide from $99 for the first month ($190–$199/month ongoing; Affirm from ~$25/mo) offers the highest value per percentage of weight lost. Phentermine is cheap ($30–$75) but produces only 3%–5% weight loss and cannot be used beyond 12 weeks.

Access the #1 and #2 Ranked Medications. Today.

Semaglutide from $99 1st mo promo. Tirzepatide from $99 1st mo promo. Doctor-supervised, 503A accredited, with Affirm financing.

Get Started

Clinical References

  1. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 387(3), 205–216.
  2. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 384(11), 989–1002.
  3. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity (SELECT). NEJM, 389(24), 2221–2232.
  4. Apovian, C. M., et al. (2015). Pharmacological management of obesity (AHA/ACC/TOS). JCEM, 100(2), 342–362.

Disclaimer: Mounjaro®, Zepbound®, Ozempic®, and Wegovy® are registered trademarks of their respective owners (Eli Lilly and Company, Novo Nordisk). Telehealth FX is an independent telehealth platform and is not affiliated with, endorsed by, or sponsored by these trademark owners. Compounded medications are prepared by state-licensed compounding pharmacies pursuant to a patient-specific prescription and are not reviewed or approved by the FDA for safety or efficacy.